11,652 Shares of Moderna, Inc. $MRNA Acquired by Gallagher Capital Advisors LLC

Gallagher Capital Advisors LLC acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,652 shares of the company’s stock, valued at approximately $2,244,000. Moderna comprises 1.1% of Gallagher Capital Advisors LLC’s holdings, making the stock its 25th largest position.

Other hedge funds have also recently modified their holdings of the company. TD Waterhouse Canada Inc. grew its holdings in shares of Moderna by 2.6% in the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock valued at $246,000 after acquiring an additional 85 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in Moderna by 8.8% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 1,976 shares of the company’s stock worth $381,000 after acquiring an additional 159 shares during the period. Assetmark Inc. lifted its holdings in Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares during the period. Versant Capital Management Inc boosted its position in Moderna by 13.8% in the third quarter. Versant Capital Management Inc now owns 2,491 shares of the company’s stock worth $480,000 after purchasing an additional 302 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in Moderna by 21.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,153 shares of the company’s stock worth $63,000 after purchasing an additional 387 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 40,281 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $146.07, for a total transaction of $5,883,845.67. Following the sale, the president directly owned 1,562,029 shares of the company’s stock, valued at $228,165,576.03. This represents a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 118,882 shares of company stock worth $16,862,280. Company insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MRNA. Bank of America raised Moderna from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 19th. Sanford C. Bernstein reissued a “market perform” rating on shares of Moderna in a report on Friday, September 25th. Piper Sandler restated an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd. Citigroup downgraded shares of Moderna from a “neutral” rating to a “sell” rating and raised their price objective for the stock from $60.00 to $80.00 in a report on Wednesday, September 30th. Finally, William Blair assumed coverage on shares of Moderna in a research report on Friday, August 28th. They issued an “outperform” rating on the stock. Seven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $78.17.

Moderna Stock Performance

NASDAQ:MRNA opened at $225.00 on Friday. The company has a market capitalization of $89.83 billion, a P/E ratio of -28.16 and a beta of 1.09. The business has a fifty day simple moving average of $140.07 and a two-hundred day simple moving average of $84.92. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $225.00.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.13) EPS. On average, analysts expect that Moderna, Inc. will post -6.11 earnings per share for the current year.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Cancer-vaccine initiative drives investor enthusiasm: Reports that the NIH plans to expedite cancer-vaccine development, along with details of a planned national effort, led investors to view Moderna as a major potential beneficiary because of its mRNA platform and oncology ambitions. Moderna stock jumps on planned national cancer vaccine effort
• Positive Sentiment: Nasdaq-100 inclusion supports demand: Moderna rejoined the Nasdaq-100, replacing Warner Bros. Discovery. The change may prompt buying by index-tracking funds and increases the company’s visibility with institutional investors after its substantial long-term share-price recovery. Moderna returns to the Nasdaq-100
• Positive Sentiment: Broad biotech rally adds momentum: Vaccine and biotechnology stocks rose broadly, with Moderna among the prominent gainers. Sector-wide strength likely amplified the company-specific rally. Biotech stocks rally
• Neutral Sentiment: Pipeline narrative is expanding beyond COVID-19: Coverage highlighted Moderna’s development of flu vaccines and cancer therapies, reinforcing the company’s strategy to build additional commercial franchises. However, these programs remain dependent on clinical, regulatory and commercial execution. The science and politics of the new mRNA flu vaccine
• Negative Sentiment: Valuation and execution concerns remain: Morgan Stanley maintained a Hold rating, while reports emphasized the challenge of manufacturing a potential cancer franchise at scale. These issues could limit further gains if clinical progress does not translate into sales and profits. Moderna gets a Hold from Morgan Stanley
• Negative Sentiment: Insider selling is a cautionary signal: Coverage noted that insiders have trimmed holdings as the stock has surged, potentially signaling profit-taking or caution after the steep rally. Moderna insiders trim holdings

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.